Is Exelixis, Inc. (EXEL) Among the Best Under-the-Radar Stocks to Invest In?

Exelixis, Inc. (NASDAQ:EXEL) is one of the 10 Best Under-the-Radar Stocks to Invest In.

On June 22, Exelixis, Inc. (NASDAQ:EXEL) reported final Phase 3 STELLAR 303 data, which showed zanzalintinib plus atezolizumab produced a non-statistically significant overall survival trend. It was in favor of the combination among metastatic colorectal cancer patients without active liver metastases. The company reported a median overall survival of 15.9 months for the combination as compared to 12.7 months for regorafenib. It also disclosed a hazard ratio of 0.83 and P = 0.1185, and no new safety signals emerged.

The oncology firm also said STELLAR 303 previously achieved its other dual primary endpoint by delivering a statistically significant survival benefit in the intention-to-treat population. Detailed findings were presented at the 2025 European Society for Medical Oncology Congress and published in The Lancet. The corporation noted the FDA accepted its New Drug Application for the combination in February 2026 and assigned a target action date of December 3, 2026.

Is Exelixis, Inc. (EXEL) Among the Best Under-the-Radar Stocks to Invest In?

Pixabay/Public domain

Exelixis, Inc. (NASDAQ:EXEL) is an oncology company. Its products include cabometyx, cometriq, and cotellic.

While we acknowledge the risk and potential of EXEL as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than EXEL and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1